JERUSALEM – Teva Pharmaceutical Industries (NYSE: TEVA) expects to work productively with the incoming Trump administration in the United States, chief executive Richard Francis said on Wednesday.
“Our job, as always, is to work productively with any administration, and we’ve shown we can do that, and we will absolutely do that,” Francis told Reuters after the Israeli drugmaker issued strong third-quarter results.
He said, though, it wouldn’t be clear until after Donald Trump takes office what his healthcare and pharmaceutical policies will be.
Francis also said that he expects 2025 to be “more of the same” for the company, with growth in branded drugs, continuing growth in its generics drugs business, plus more sales of biosimilars.
(Source: Reuters)
NYSE: TEVA Teva Pharmaceutical
